阿托伐他汀治疗不稳定性心绞痛的临床疗效及安全性观察

目的：评价阿托伐他汀治疗不稳定性心绞痛患者的疗效及安全性。方法：将100例患者随机分为两组，对照组50例给予常规治疗；阿托伐他汀治疗组50例，在常规治疗的基础上加用阿托伐他汀，疗程12周。观察其治疗前后主要症状和体征，每博量（sv）、每分博出量（CO）、射血分数（EF）和舒张功能指标（E／A）等心功能指标，以及血清总胆固醇（Tc）、甘油三酯（TG）、高密度脂蛋白（HDL．C）和低密度脂蛋白（LDL．c）和高敏c-反应蛋白（hs．CRY）等血液生化指标。结果：治疗组缓解心绞痛的显效率为28％，总有效率为96％，改善心电图的的显效率为22％，总有效率为84％，速效扩冠药物停减率为60．62％，经统计学处理均优于对照组（P〈O．05）；治疗组治疗后的心功能各指标均显著优于治疗前（P〈0．01），且优于对照组（P〈0．05）。治疗组患者治疗后TC、TG、HDL—C、LDL．C及hs—CRP较治疗前降低（P〈0．05），且优于对照组（P〈0．05）。两组患者治疗前后肝肾功能检查均在正常范围且无明显不良反应。结论：阿托伐他汀治疗不稳定性心绞痛疗效确切且安全可靠。

The Evaluation of Efficacy and Safety of Atorvastatin on Patients with Unstable Angina Pectoris

Objective： To investigate the clinical efficacy and safety of Atorvastatin on patients with unstable angina pectoris. Methods： A total of 100 patients with unstable angina pectoris were divided into two groups： 50 cases with regular treament as control group and 50 cases with regular treament and Atorvastatin as treatment group. Pretherapy and post-treatment variables of two groups were compared. Results： Atorvastatin could improve the clinical symptoms（96%） and electrocardiogram（84%） of the patients, which had the significant difference compared to the control group（P〈0.05）. The treatment group had a better fast-acting dilate coronary drug reduc- tion rate than the control group（P〈0.05）. There were significant differences in the heart function indexes in treatment group before and af- ter treatment, which were superior to those of control group （P〈0.05）, including SV, CO, EF and E/A. TC, TG, HDL-C, LDL-C, and hs- CRP were significantly different between before and after treatment in the treatment group （P〈0.05）. They were better than those of control group （P〈0.05）. Conclusion： It is safe and effective for Atorvastatin treating unstable angina pectoris patients.